Speeches by Beales.

“Your model comparing borrowing costs looks very much at private sector borrowing based on a repayment model over time. There are obviously other types of public-private finance initiatives or partnerships in the development sector, some of which use asset exchanges. On large hospital sites or large public sector sites,…”

“Very few contracts or funding pots in any Government areas give funding security for 20 years. Spending review periods are three years. This is not a unique challenge. Why is the health system so hesitant and cautious in this space, where perhaps others in the public sector are not?”

“What is your judgment about the benefits of the lower cost of public borrowing that generally could be secured compared to private resource borrowing, versus other financial considerations such as the speed of delivery and inflationary pressures, particularly in the construction sector? Do you have any sense from the e…”

“Does anyone else on the panel have any thoughts about how that might be better unlocked?”

“Turning to section 106 and CIL, Martin, do you have a sense as an organisation of how much CIL and section 106 that can be utilised for healthcare at the moment is unspent?”

“If the system were able to use some of that capital funding to switch to provide security in terms of revenue-based pressures over a set lease term, would that help in the system? At the moment, technically CIL is capital funding, but there are examples of some being used to subsidise revenue pressures in other service…”

“Is there comparative data on the speed of the delivery of the PPP projects versus the purely public sector projects?”

“Kieran and Simon, is there any similarity in additional structured pricing options, depending on the level of support, or is it just one flat price?”

“Is a blood test clinically indicated? Are they recommended as part of the normal treatment pathways?”

“Human to human interaction?”

“The extra support you provide, is that all benchmarked into the price; there is no additional pricing? Are there additional options you offer to people with varying prices attached?”

“How much is that?”

“If any of those issues come back indicative of potential low risk or high risk or diagnosed conditions, what happens to the patient then?”

“Good morning. The NICE appraisal talked about the importance of wraparound care associated with the treatments, and the NHS England proposal talked about a number of different appointments that people required. Simon, I think you touched on the number of GP appointments. What does the wraparound care offer look like fo…”

“Is the nutritionist, etc, all included in the cost up front?”

“Have any of you had data based on what your patients are sharing with you around that behaviour change point? I think that would be very interesting for the Committee to see.”

“Is that one-to-one support or signposted?”

“Would that lead to additional services that you would provide and charge for or—”

“That would be helpful. Thank you very much.”

“Do you have any data around the number of patients you will refer back to the NHS or their GP about matters that you have looked into and tested for? If someone was struggling with their mental health, do you refer them back? I am not saying you should not do that, but do you have any sense of the number? I think someo…”